InterX news

NeoTX announced today the acquisition of InterX. InterX, is a drug discovery company utilizing advanced proprietary tools of biomolecular computation for the discovery and design of novel therapeutic molecules based on Nobel Prize Laureate Prof Michael Levitt’s discoveries. These tools allow a detailed quantum mechanical process assessment of biochemical interactions resulting in faster, more accurate and efficient drug discovery. In addition to the discovery engine, this acquisition al

InterX, Inc., a privately-owned company, Philochem, a wholly owned subsidiary of Philogen S.p.A., a publicly-listed company, and Scripps Research, a non-profit American medical research facility, today announced the signature of a research collaboration to discover new small molecule therapeutics using InterX’s proprietary computational chemical biology software platform and Philochem’s and Scripps’ proprietary DNA-Encoded Chemical Library (DEL) technology.

This coll